Roche bids for remainder of Genentech

Stephen Beard Jul 21, 2008
HTML EMBED:
COPY

Roche bids for remainder of Genentech

Stephen Beard Jul 21, 2008
HTML EMBED:
COPY

TEXT OF STORY

Bob Moon: Genentech is the largest maker of cancer treatments in the U.S. Almost half the biotech giant is controlled by the Swiss pharmaceutical giant Roche.

Now, Roche has decided it wants to control the whole company.

Marketplace’s Stephen Beard has more from London


Stephen Beard: Roche is offering almost $48 billion for the outstanding minority stake in Genentech. If it goes ahead, this will be the biggest pharmaceutical deal for five years.

Some analysts say it looks like a smart move. With the dollar so weak, Roche will be gaining the rest of Genentech on the cheap. And Genentech is doing well. Its researchers have already provided Roche with their best-selling cancer therapies.

But Jeff Goldfarb of the financial website Breaking Views has his doubts about the deal.

Jeff Goldfarb: Genentech has really thrived at arms length even though it has been controlled by Roche, but taking 100 percent suggests there may be some structural changes that could change the way things operate and may not deliver the same benefits.

He also believes that Roche will have a fight on its hands: that the minority shareholders in Genentech will hold out for a much better price.

In London, this is Stephen Beard for Marketplace.

There’s a lot happening in the world.  Through it all, Marketplace is here for you. 

You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible. 

Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.  

Need some Econ 101?

Our new Marketplace Crash Course is here to help. Sign-up for free, learn at your own pace.